Introduction
Amyotrophic lateral sclerosis (ALS) is a pernicious neurodegenerative disease defined by the selective degeneration of central nervous system (CNS) motor neurones, leading to progressive paralysis culminating in death (Boillee et al., 2006) . Despite accounting for only 20% of human familial ALS cases -and 2% of all cases (Kiernan et al., 2011) -mutations to the metalloenzyme Cu/Zn superoxide dismutase (SOD1) were the first discovered genetic cause of ALS and have therefore been extensively studied. Moreover, transgenic rodents expressing mutant SOD1 were the earliest animal models of the disease (Gurney et al., 1994; Nagai et al., 2001; Wong et al., 1995) and they remain the most robust murine models of ALS (Mcgoldrick et al., 2013) . In these models, the animals selectively develop a motor neurone degeneration phenotype with CNS pathology characteristic of the human disease, even though the causal mutant SOD1 transgene is expressed ubiquitously (Yamanaka et al., 2008) .
Clear explanations for why motor neurones are particularly sensitive to degeneration, and why ALS-causing mutations only appear to adversely affect cells of the CNS (despite being expressed ubiquitously) remain elusive. However, in the context of SOD1, a prevailing view is that mutations imbue the protein with a toxic gain-of-function leading to misfolding and aggregation (Cleveland and Rothstein, 2001) , and an underpinning reason for this may lie in the requirement of the functional SOD1 dimer for one catalytic copper and one structural zinc atom per subunit (Hough and Hasnain, 1999) . It has previously been reported that ALS-causing SOD1 mutations can alter the protein's zinc-binding site, leading to decreased affinity and enhanced protein damage due to T tyrosine nitration (Crow et al., 1997; Lyons et al., 1996) . Contrarily, it has been shown that mutant SOD1 presents with significantly decreased copper content regardless of the mutant copper binding affinity (Bourassa et al., 2014; Ip et al., 2011) and, importantly, that the majority of metal-deficient mutant SOD1 in vivo is in a copper-deficient form (Roberts et al., 2014) . Taken together, these findings lend support to a role for metal-deficient SOD1 in the pathogenesis of ALS (Hilton et al., 2015) .
Previous work by our group using the SOD1 G37R mouse model demonstrated that with ubiquitous mutant SOD1 overexpression, zinc levels are significantly elevated in all tissues, including the CNS, to match its elevated requirement in SOD1 (Hilton et al., 2016 ). In contrast, while copper levels in the peripheral tissues are proportionately elevated to match the increase in SOD1, the CNS showed only marginal or insignificant increases (Hilton et al., 2016) . This indicates a potential restriction to endogenous copper bioavailability that selectively affects the CNS; a possibility supported by data that show the natural turnover rate for copper is 20 to over 2000 times slower in the CNS compared to other tissues (Levenson and Janghorbani, 1994) . Further to this, the assessment of copper transporters and chaperones such as copper transporter 1 (CTR1) in several mutant SOD1 mouse models showed significant changes in spinal cord expression levels independent of the mutant SOD1 protein's copper-binding ability (Tokuda et al., 2009; Tokuda et al., 2013) . Whilst the direction of these changes appears conducive to copper accumulation (e.g. increased CTR1 expression), direct and indirect evidence for copper-deficient SOD1 in the mutant SOD1 mouse spinal cord (Hilton et al., 2017; Roberts et al., 2014; Tokuda et al., 2018) , suggests that these changes may in fact occur in response to unfulfilled CNS copper requirements induced by mutant SOD1 overexpression (Hilton et al., 2016) . Here, we have tested this possibility by extending our analysis of cuproenzyme function in the CNS to the ferroxidase ceruloplasmin and to the terminal complex of the mitochondrial electron transfer chain cytochrome c oxidase. To gain insight into how changes to copper-dependent processes may track with disease progression, we analysed tissues collected from mice across various stages of disease progression. Then, to determine whether increasing copper supply to the CNS may mitigate evidences for copper malfunction in the SOD1 G37R mouse spinal cord, we also examined tissues collected from SOD1 G37R mice which additionally overexpress human CTR1 (hCTR1). Our results show that cuproenzyme dysfunction is a prominent feature of the mutant SOD1 mouse CNS, and that hCTR1 overexpression partially restores proper functionality of these enzymes by improving available copper levels.
Methods

Mouse lines
All research involving live mice was approved by a University of Melbourne Animal Experimentation Ethics Committee (clearance #1111947 and #1312908) and conformed with the guidelines of the Australian Health and Medical Research Council. Hemizygous mice expressing a transgene for human SOD1 containing the G37R substitution mutation (SOD1 G37R ) on the congenic C57Bl/6 background were used as an ALS model (Wong et al., 1995) . Hemizygous mice expressing wild-type human SOD1 on the congenic C57Bl/6 background were used as a control line, where in spite of human SOD1 being expressed at levels comparable to the SOD1
G37R
, these mice do not develop an overt ALS-like phenotype at the ages studied (Graffmo et al., 2013) . Both lines were purchased from the Jackson Laboratories (strains B6·Cg-Tg(SOD1*G37R)42Dpr/J and B6·Cg-Tg(SOD1)2Gur/J, respectively) and colonies maintained by breeding hemizygous transgenic mice with non-transgenic C57Bl/6 mice. Non-transgenic littermates from the SOD1 G37R colony were used as an additional control.
Approximately equal numbers and gender proportions of mice were allocated to age groups of 13, 17, 21 and 25 weeks for SOD1 G37R mice and non-transgenic littermates, and age groups of 13, 25, 33 and 50 weeks for SOD1 WT mice. Genotypes were established using the Extract-N-Amp Plant PCR kit (Sigma) as per manufacturer's instructions. Tail snips from each mouse were collected to extract DNA and prepare PCR products which were ran on 1.7% agarose gels at 100 V for 30 min and then imaged with the UVP BioDoc-It System (Pathtech). Hemizygous mice expressing the human copper transporter 1 (hCTR1) on the congenic C57Bl/6 background were used as described previously (Roberts et al., 2014) and mated with SOD1 G37R mice (above) to generate the following four genotypes: non-transgenic, SOD1 G37R , hCTR1, and hCTR1xSOD1
.
Phenotype assessment
SOD1
G37R mice and non-transgenic littermates were assessed for phenotype progression using the rotarod assay for locomotive function and measuring body weight. Mice were habituated to the rotarod assay for 5 days prior to recording performance. During the recording period the rotation speed of the rotarod was accelerated from 4 rpm to 40 rpm over a 180 s period with the time taken to fall off the rotarod (latency to fall) recorded for each mouse. During assessment each mouse was subjected to two independent runs on the rotarod, twice weekly, with only the higher latency to fall score used for subsequent analysis. All mice were assessed for weight once weekly until age of tissue collection.
Tissue collection and processing
Mice were anaesthetised by intraperitoneal injection of ketamine (120 mg kg and spinal cord tissues were excised, snap frozen on dry ice, then stored at −80°C. Mouse and human tissue samples were homogenised using polypropylene pestles in TBS supplemented with 0.5% (v/v) phosphatase inhibitor cocktail 2 (Sigma), 2% (v/v) Complete EDTA-free protease inhibitor (Roche), and 5% (v/v) DNAse. Homogenates were then separated into TBS-soluble and TBS-insoluble fractions by centrifugation (18,000 x g, for 30 min at 4°C). TBS-insoluble pellets were resuspended in the TBS homogenising buffer described above and vortexed thoroughly. Protein content of all soluble and insoluble samples was determined using the BCA Assay (Thermo Scientific) then all samples normalised to a consistent protein concentration using TBS homogenising buffer described above.
SDS-PAGE and immunoblotting
TBS-soluble samples were prepared in denaturing sample buffer containing 62.2 mM Tris, 5% (v/v) glycerol, 2% (w/v) SDS, and 0.0025% (w/v) bromophenol blue prior to loading onto 4-12% NuPAGE Novex Bis-Tris Midi gels (Life Technologies) and electrophoresed at 200 V for 40 min using MES SDS running buffer (Life Technologies). TBS-insoluble fractions were processed in 1% (v/v) Triton-× 100 detergent (Calbiochem) and then subjected to additional centrifugation (18,000 x g, 3 min, 4°C) to separate out indissoluble elements prior to sample buffer addition and loading. Resolved proteins were transferred onto PVDF membranes using iBlot gel transfer stacks (Life Technologies) as per manufacturer's instructions. Membranes were blocked for 1 h in PBS supplemented with 0.05% (v/v) Tween-20 (Chemsupply) and 4% (w/v) skim milk powder prior to incubation with primary antibodies in the above blocking buffer, overnight at 4°C. Primary antibodies used were raised to detect human SOD1 (Abcam; 1:100,000), mouse SOD1 (Abnova; 1:1000), ceruloplasmin (DAKO; 1:1000), GAPDH (Cell Signaling; 1:5000), or β-actin (Cell Signaling; 1:3000). Horseradish peroxidase-conjugated secondary antibodies for anti-rabbit IgG (Cell Signaling; 1:5000) or anti-mouse IgG (Cell Signaling; 1:5000) targeting primary antibodies were then used for the relevant primary antibodies. Immunoreactive protein bands were visualised by adding Enhanced Chemiluminescence (ECL Advance, GE Healthcare) to membranes and detecting luminescence using a FujiFilm LAS-3000 imager. Quantitation of immunoreactivity was performed using ImageJ software on TIFF file images.
Native immunoblotting
Detection of misfolded SOD1 requires native conditions (Bosco et al., 2010) , therefore, desired TBS-soluble sample volumes were prepared in non-reducing and non-denaturing sample buffer containing 50 mM Tris supplemented with 5% (v/v) glycerol and 0.0025% (w/v) bromophenol blue. As heating was avoided, TBS-soluble samples were vortexed and loaded directly onto 12% Novex Tris-Glycine gels (Life Technologies) and resolved by electrophoresis at 125 V for 120 min, then transferred onto PVDF membranes using iBlot gel transfer stacks. Membranes were blocked for 1 h in PBS supplemented with 0.05% (v/ v) Tween-20 (Chemsupply) and 4% (w/v) skim milk powder prior to incubation with primary antibodies in blocking buffer, overnight at 4°C. Misfolded SOD1 was probed for using A5C3 (1:250), B8H10 (1:250) and C4F6 (1:250) primary antibodies (MediMabs) under native conditions. These misfolded SOD1 antibodies were developed to target different epitopes specific to misfolded human SOD1 without detecting natively folded forms of SOD1 (Bosco et al., 2010; Pickles et al., 2016) . Horseradish peroxidase-conjugated secondary antibodies for antimouse IgG (Cell Signaling; 1:5000) targeting primary antibodies were then used, with bands imaged and quantitated as described above.
SOD1 activity
TBS-soluble tissue samples were assessed using a pyrogallol based assay (Li, 2012; Marklund and Marklund, 1974) , where pyrogallol oxidation induced by reactions with superoxide radicals produces a measurable colour change that can be inhibited by SOD1 activity. This assay measures the activity of both endogenous mouse and human forms of SOD1 thereby assessing total SOD1 activity within each sample. Inhibition of copper-dependent enzyme activity was achieved using potassium cyanide (KCN) for the purpose of measuring activity attributable to SOD1 (Marklund and Marklund, 1974) . Therefore, supernatant samples were added to plate wells in duplicate preloaded with H 2 O or 10 mM KCN in H 2 O for direct comparison. Pyrogallol (Sigma) was made up to a final concentration of 200 μM in 50 mM Tris buffer supplemented with 1 mM EGTA and corrected to a physiological pH 7.4, then allowed to reach steady-state equilibrium for 1 min. This reaction buffer was added to each well to initiate the assay and then monitored in a plate reader for change in absorbance at 325 nm every 30 s for 30 min at 25°C. SOD1 activity was calculated using the initial linear phase and expressed as percentage relative to the earliest age group for each phenotype, or relative to non-transgenic littermates in hCTR1 study analyses. Specific activity was calculated as SOD1 activity relative to total human SOD1 levels or endogenous mouse SOD1 levels (non-transgenic mice) and was expressed as relative percentage as per SOD1 activity calculations.
Ferroxidase activity
The activity of ceruloplasmin was measured using an established ferroxidase assay (Wong et al., 2014) where ceruloplasmin catalyses the production of ferric (Fe 3+ ) iron from ferrous (Fe 2+ ) iron, and loading of Fe 3+ onto transferrin corresponds to a measurable colour change based on diferric transferrin production. Due to phosphate interference with ferroxidase-based assays, the insoluble fractions were resuspended in TBS (described above) and aliquots of these fractions supplemented with 1% (v/v) Triton-× 100 to permeabilise cells and partially solubilise the membranes before centrifugation (18,000 ×g, 3 min, 4°C) and collection of the Triton-× 100 soluble fraction. Fractions were assessed for protein concentration using the BCA assay and normalised to a consistent protein concentration. For each assay run, fresh solutions of 250 μM human apotransferrin (Sigma) and 1 mM FeSO 4 were prepared in N 2 gas-purged dH 2 O to mitigate ferroxidase-independent oxidation of iron. Wells were then loaded with HEPES-buffered saline (50 mM HEPES, 150 mM NaCl, pH 7.2) for optimal physiological assay conditions (Wong et al., 2014) followed by 50 μM human apotransferrin solution. Reactions were initiated with 100 μM FeSO 4 solution and immediately monitored in a plate reader for change in absorbance at 460 nm every 10 s for 5 min at 25°C. Ceruloplasmin ferroxidase activity was calculated using the initial linear phase and expressed as a percentage relative to the earliest age group for each genotype, or relative to non-transgenic littermates in hCTR1 study analyses. Specific activity was calculated as ceruloplasmin activity relative to total ceruloplasmin levels and was expressed as a relative percentage as per ceruloplasmin activity calculations.
Mitochondrial fraction purification
To collect intact mitochondria, SOD1 G37R mice and non-transgenic littermates were culled by cervical dislocation at 25 weeks of age without perfusion followed by immediate dissection of fresh liver and spinal cord tissues. Freshly dissected tissues were quickly placed into ice-cold isolation buffer A (210 mM mannitol, 70 mM sucrose, 5 mM HEPES, 1 mM EGTA and 0.5% (w/v) BSA, pH 7.2 corrected with KOH). Tissues from each mouse were transferred onto a glass petri dish on ice then minced and weighed before placement in a Dounce homogeniser with 2-5 mL of isolation buffer A. The loose pestle was used to perform 4 passes followed by 8 passes with the tight pestle, then the homogenates were transferred to 15 mL tubes and subjected to centrifugation at 650 ×g for 10 min. Sample supernatants were then transferred to fresh 15 mL tubes and subjected to further centrifugation at 5000 ×g for 10 min. The resulting supernatants were discarded and pellets resuspended in 5-6 mL of isolation buffer A before centrifugation at 650 ×g for 10 min and collection of resulting supernatants. Supernatants were again subjected to centrifugation at 5000 ×g for 10 min with the resultant pellets resuspended in 3 mL of 14% Percoll prepared in isolation buffer B (320 mM sucrose, 10 mM Tris and 1 mM EDTA, pH 7.4 corrected with HCl). Suspensions were layered on top of a premade Percoll gradient made from 4 mL of 40% Percoll and 6 mL of 19% Percoll (both prepared in isolation buffer B) and subjected to centrifugation at 30700 ×g for 15 min. Material at the 40% and 19% Percoll interface was collected and volume of the collected material recorded before diluting to 1:4 with isolation buffer B. Samples were subjected to centrifugation at 16000 ×g for 20 min with resulting supernatants discarded and pellets resuspended in 1 mL of isolation buffer B supplemented with 0.01% (w/v) BSA. Samples were then transferred to 1.5 mL microfuge tubes and subjected to centrifugation at 7500 x g for 10 min followed by removal of supernatants and resuspension of pellets in 50-100 μL isolation buffer B. Protein concentration of mitochondrial preparations were measured using the BCA assay then normalised with isolation buffer B and stored at −80°C.
Cytochrome c oxidase (CCO) activity
Activity of CCO was investigated based on a described assay (Trounce et al., 1996) that measures the rate at which the reduced form of cytochrome c (ferrocytochrome c) is oxidised by CCO to ferricytochrome c. Initially, equal volumes of 8 mM cytochrome c and 100 mM Lascorbate dissolved in 10 mM KH 2 PO 4 buffer (pH 7.4) were combined to reduce the cytochrome c. The resultant ferrocytochrome c was separated by liquid chromatography using porous Sephadex G-25 suspended in 10 mM KH 2 PO 4 buffer as the stationary phase. To minimise cytochrome c re-oxidation, the KH 2 PO 4 buffer was N 2 gas-purged before Sephadex G-25 suspension and run through the column 5 times to remove oxygen from the stationary phase. Elution was performed with KH 2 PO 4 buffer and the middle ¾ of the cytochrome c band was collected and aliquoted into N 2 gas-purged 1.5 mL microfuge tubes for storage at −80°C. Aliquots of ferrocytochrome c were measured for concentration using a plate reader set to absorbance at 550 nm and calculated using Beer's law (extinction coefficient of 27.7 mM −1 cm −1 ).
To measure CCO activity mitochondrial preparations were added to plate wells in duplicate with or without 2 mM KCN to determine KCN sensitive copper-dependent enzymatic activity attributed to CCO. Each well was then loaded with ferrocytochrome c solution made to a final concentration of 20 μM using N 2 gas-purged KH 2 PO 4 buffer to initiate reaction and measured in a plate reader for change in absorbance at 550 nm every 3 s for 90 s at 25°°C. CCO activity was determined by calculating the rate of absorbance change through the linear phase of each sample and subtracting the KCN-insensitive rate. Control wells containing equivalent volumes of KH 2 PO 4 buffer ± KCN were also used to control for buffer interference and CCO-independent activity. CCO activity was expressed as a percentage relative to non-transgenic mice.
Citrate synthase activity
As CCO activity may be affected by mitochondrial numbers in each tissue sample, the copper-independent enzyme citrate synthase was measured as an additional control based on a published method (Trounce et al., 1996) . Initially, 125 mM Tris buffer (pH 8.0) was made up and used to prepare 2 mM DTNB aliquots while 6 mM acetyl-CoA aliquots were made up with dH 2 O. Plate wells were loaded with or without 2 μg of mitochondrial protein then 10 μL DTNB solution and 10 μL acetyl-CoA solution were added with Tris buffer used to make each well up to 190 μL. To initiate the reaction, 10 μL of 10 mM oxaloacetate solution made up fresh in dH 2 O and mixed thoroughly was added to each well and measured on a plate reader for change in absorbance at 412 nm every 3 s for 150 s at 25°C. Citrate synthase activity was determined by calculating the rate of absorbance change through the linear phase of the reaction. Wells without sample were used to control for buffer interference and citrate synthase-independent activity. Citrate synthase activity was expressed as a percentage relative to non-transgenic mice.
Inductively coupled plasma mass spectrometry (ICP-MS)
Frozen sections of tissue were weighed and then measured for total levels of copper, zinc, magnesium and selenium according to a previously described protocol (White and Cappai, 2003) . Frozen tissue sections were transferred to 1.5 mL microfuge tubes, freeze-dried and then lyophilised samples were digested overnight in calculated volumes of concentrated nitric acid (65% HNO 3 ). Samples were then incubated at 90°C for 20 min then an equivalent volume of hydrogen peroxide (30% H 2 O 2 ) added. Samples were allowed to equilibrate for approximately 30 min before further heating at 70°C for 15 min. The decrease in volume after these steps was recorded and the average decrease in volume was determined before samples were diluted with 1% HNO 3 by a predetermined factor which was recorded for subsequent calculations. Metal content measurements were made using an Agilent 7700 Series ICP-MS instrument with a Helium Reaction Gas Cell under routine multi-element operating conditions. The instrument was calibrated using 0, 5, 10, 50, 100 and 500 parts-per-billion (ppb) of certified multielement ICP-MS standard calibration solutions for selected elements. A standard solution made from 200 ppb of yttrium (isotope Y 89 ) was employed as an internal control. Results for each element were initially measured as ppb and then expressed as μg/g wet weight tissue.
Statistical analyses
All data sets were subjected to the Grubbs' outlier test (α = 0.05) and were subjected to parametric statistical tests, unless in cases where the data set was determined to be non-parametric using the D'AgostinoPearson normality test. Rotarod and weight data were assessed using a two-tailed repeat measures ANOVA test with the Bonferroni post hoc test. Data sets comparing two groups were subjected to the Student's ttest or Mann Whitey test, whilst multiple group analyses were performed using the one-way ANOVA test. For data sets comparing agedependent changes across multiple groups, data were assessed using the Dunnett's multiple comparisons post hoc test with the earliest age set as the reference group. For the remaining data sets comparing multiple groups, the Sidak's multiple comparison post hoc test was used to investigate SOD1 G37R mice relative to non-transgenic and hCTR1xSOD1 G37R mice. All data are presented as mean ± standard error of the mean (S.E.M). Statistical significance was determined as P < .05 with significant P values labelled within each respective figure. All analyses were performed using GraphPad Prism.
Results
Enzymatically inactive mutant SOD1 accumulates with disease progression in the SOD1 G37R mouse spinal cord
To determine whether the copper-dependent activity of SOD1 changes relative to disease progression in SOD1 G37R mice, we assessed tissues collected from the mice at 13, 17, 21 and 25 weeks of age, spanning early through to late stage disease progression. SOD1 G37R mice were monitored for phenotypic progression and showed a significant decrease in locomotor function via rotarod, whereas mouse weight was not statistically different compared to non-transgenic littermates (Fig. 1A, B) . We then measured abundance of the SOD1 protein and compared this to measureable SOD1 activity in both spinal cord and liver tissues. Spinal cord tissue from SOD1 G37R mice showed a clear progressive increase in human SOD1 levels, reaching significance at 21 weeks of age (Fig. 1C) . In contrast, human SOD1 levels remained constant in the SOD1 WT mice, even up to 50 weeks of age (Fig. 1D) . The observed accumulation of human SOD1 in the SOD1 G37R mice was selective for the spinal cord, with no change in protein level observed in the non-disease affected liver tissues from either the SOD1 G37R or SOD1 WT mice (Fig. 1C, D) . Additionally, assessment of endogenous mouse SOD1 protein levels showed that the observed increase in SOD1 in the SOD1 G37R mouse spinal cord was selective for the human mutant form, with endogenous mouse SOD1 protein levels remaining constant across all tissues and mouse models analysed (Fig. 1E-G) . Measurement of copper-dependent SOD1 activity was performed using the previously described pyrogallol-based assay (Li, 2012; Marklund and Marklund, 1974) which is indiscriminate for mouse and human SOD1 activity. Assessment of the spinal cord tissue showed that, as anticipated based on SOD1 protein levels, SOD1 activity remained unchanged in SOD1
WT and non-transgenic mice (Fig. 1J, L) , thereby contributing to maintenance of stable SOD1 specific activity (Fig. 1K,  M) . Moreover, and contrary to levels of human SOD1 (Fig. 1C) , SOD1 activity in the SOD1 G37R spinal cord also remained unchanged across all stages of disease progression (Fig. 1H ), equating to a significant decrease in SOD1 specific activity which progressively worsened along with disease symptoms (Fig. 1I ). No differences in either SOD1 activity or specific activity were observed in the peripheral liver tissue across all genotypes ( Supplementary Fig. 1 ), which indicated a CNS selective effect for mutant human SOD1.
3.2. Enzymatically inactive ceruloplasmin accumulates with disease progression in the SOD1 G37R mouse spinal cord, but cytochrome c oxidase activity is not affected
The progressive accumulation of inactive SOD1 in the SOD1 G37R mouse spinal cord, but not the liver (Fig. 1) , is consistent with a previous report which directly measured copper-deficient SOD1 in the spinal cords of mutant SOD1 transgenic mice (Roberts et al., 2014) , and our study that showed endogenous copper availability in the CNS fails to satiate the increased requirement for copper in mutant SOD1 overexpressing mice (Hilton et al., 2016) . Collectively, these data are consistent with the overexpressed mutant SOD1 creating conditions, in which the availability of endogenous copper to copper-dependent cuproenzymes is disrupted selectively in the CNS. To investigate whether other cuproenzymes are affected in the SOD1 G37R mouse spinal cord we assessed ceruloplasmin and cytochrome c oxidase levels and enzymatic function.
Ceruloplasmin is a copper-dependent ferroxidase responsible for systemic copper transport as well as cellular iron efflux in CNS (Ramos et al., 2016) . Changes in ceruloplasmin have been previously reported in ALS sera (Domzal and Radzikowska, 1983; Goodall et al., 2008; Torsdottir et al., 2000) , but the relationship between protein expression and function of ceruloplasmin in CNS tissues is yet to be established. Here, we initially assessed the levels of ceruloplasmin in SOD1
G37R
spinal cord and showed an age-dependent increase reaching significance at 25 weeks of age ( Fig. 2A) . The observed elevation was found to occur in absence of changes to ceruloplasmin levels in the SOD1 G37R liver, or the spinal cord and liver tissues from SOD1 WT and non-transgenic mice ( Fig. 2A-C) . The ferroxidase activity of ceruloplasmin was assessed based on a previously described protocol measuring the change in transferrin iron loading (Wong et al., 2014) . Whilst ceruloplasmin activity and specific activity for the SOD1 WT and non-transgenic spinal cords were unchanged ( Fig. 2F-I ), the SOD1 G37R mice displayed an age-dependent decrease in ferroxidase activity that reached significance at 17 weeks (Fig. 2D) . Increased ceruloplasmin protein levels and decreased activity the time points at which tissues were collected for analyses. Western blot analysis was used to assess levels of transgenic human SOD1 in spinal cords and livers collected from SOD1 G37R (C) and SOD1 WT mice (D) as well as endogenous mouse SOD1 in SOD1 G37R (E), SOD1 WT mice (F) and non-transgenic (G) mice. Quantitation of western blot data was performed by normalising to the loading control protein GAPDH. SOD1 activity in spinal cords collected from SOD1 G37R (H), SOD1 WT mice (J) and non-transgenic (L) mice was determined using the pyrogallol-based activity assay, and for each mouse strain was expressed relative to activity measured at the youngest age shown. SOD1 specific activity in spinal cords collected from SOD1 G37R (I), SOD1 WT mice (K) and non-transgenic (M) mice represents SOD1 activity (shown in H, J and L) normalised to the amount of SOD1 protein (shown in C-G) and is expressed relative to specific activity for each mouse strain at the youngest age shown. P values shown indicate statistical difference between indicated data sets. All data are presented as mean ± S.E.M; n = 15-21 for different time points in rotarod and weight data; n = 6-8 for all SOD1 G37R and non-transgenic mouse experiments; n = 5 for all SOD1 WT mouse experiments.
translated into a significant and progressive decline in ceruloplasmin specific activity for the SOD1 G37R spinal cord from 21 weeks (Fig. 2E ).
As with SOD1 ( Fig. 1) , these data show that ceruloplasmin dysfunction in the SOD1 G37R mice progresses with symptoms of the disease and indicate its dysfunction is selective for the CNS. We then looked at cytochrome c oxidase (CCO), a copper-dependent enzyme complex responsible for the final transfer step within the mitochondrial electron transfer chain (Musatov and Robinson, 2012) . CCO has previously been shown to be impaired in the context of ALS (Fujita et al., 1996; Kirkinezos et al., 2005) . However, in this study, we observed no alteration in the activity of CCO, or expression levels of the copper-binding catalytic subunit COXII for the SOD1 G37R spinal cord (Fig. 3A, B ). Samples were purified for the mitochondrial fraction from tissues at 25 weeks of age, suggesting that CCO was not functionally impaired in these mice even near disease end-stage. As an additional marker of mitochondria, we also investigated citrate synthase, which is not dependent upon copper for its catalytic function. Consistent with the data for CCO, protein levels and activity of citrate synthase were unchanged in the spinal cord and liver mitochondrial fractions from both SOD1 G37R mice and non-transgenic littermates (Fig. 3C, D) . Collectively, while these results show that cuproenzyme dysfunction is a feature of the disease affected SOD1 G37R spinal cord, it is not consistent across all copper-dependent enzymes measured. performed by normalising to the loading control protein β-actin. Ceruloplasmin activity in spinal cords collected from SOD1 G37R (D), SOD1 WT mice (F) and nontransgenic (H) mice was determined using a transferrin-based ferroxidase activity assay and for each mouse strain is expressed relative to activity measured at the youngest age shown. Ceruloplasmin specific activity in spinal cords collected from SOD1 G37R (E), SOD1 WT mice (G) and non-transgenic (I) mice represents ceruloplasmin activity (shown in D, F and H) normalised to the amount of ceruloplasmin protein (shown in A-C) and expressed relative to specific activity for each mouse strain at the youngest age shown. P values shown indicate statistical different between indicated data sets. All data are presented as mean ± S.E.M; n = 5-8 for all SOD1 G37R and non-transgenic mouse experiments; n = 5 for all SOD1 WT mouse experiments. Fig. 3 . Cuproenzyme cytochrome c oxidase (CCO) activity in mitochondria from SOD1 G37R mice at disease end-stage. Western blot analysis was used to assess levels of the catalytic COXII subunit of CCO in mitochondria isolated from the spinal cords of 25-week old SOD1 G37R and non-transgenic (Non-Tg) mice (A). CCO activity (B) was determined as the rate of sample-mediated cytochrome c oxidation and is expressed relative to activity detected in the respective tissue from Non-Tg controls. Western blot analysis was used to assess levels of the citrate synthase in mitochondria isolated from the spinal cords of 25-week old SOD1 G37R and non-transgenic (non-Tg) mice (C). Citrate synthase activity (D) was determined as the rate of sample-mediated DTNB reduction and is expressed relative to activity detected in the respective tissue from Non-Tg controls. Quantitation of all western blot data was performed by normalising to the mitochondrial loading control protein ΤΟΜΜ20.
All data represented as mean ± S.E.M; n = 3-4 mitochondrial preparations, each of which was generated from at least one animal.
Soluble misfolded SOD1 levels do not change with disease progression in the SOD1 G37R mouse spinal cord
The presence of misfolded SOD1 in both human cases of ALS and mutant SOD1 models of the disease has been extensively reported (Da Cruz et al., 2017; Rakhit et al., 2007; Rotunno and Bosco, 2013) . Whilst the soluble form of misfolded SOD1 has been reported to be toxic, the formation of SOD1 aggregates has been proposed to act as a protective cellular response (Brotherton et al., 2013) . Moreover, because adequate delivery of copper is required for formation of stable holo-SOD1, insufficient supply of copper to SOD1 is implicated as a potential cause of SOD1 misfolding and aggregation (Bourassa et al., 2014) .
Multiple antibodies specific for different epitope regions of human SOD1 have been developed for the purpose of targeting human SOD1 only when it is putatively misfolded (Brotherton et al., 2013; Forsberg et al., 2010; Graffmo et al., 2013; Gros-Louis et al., 2010; Rakhit et al., 2007) . In this study, we utilised several of these antibodies for the misfolded SOD1 form which target separate regions within the SOD1 protein (Bosco et al., 2010; Pickles et al., 2016) . When spinal cord samples from SOD1 G37R mice were assessed, we observed a non-significant elevation in soluble misfolded SOD1 levels using the B8H10 antibody (Fig. 4A) . Additionally, at 25 weeks of age a noticeable (but also statistically not significant) drop in misfolded SOD1 levels was seen, which has been previously observed via histology in the SOD1
G37R
and SOD1 G93A mouse spinal cord (Rakhit et al., 2007) . This decrease in misfolded SOD1 labelling was attributed to motor neurone death, however, the consistent increase in human SOD1 levels shown herein (Fig. 1C) would suggest this is a misfolded SOD1-specific phenomenon.
No differences in misfolded SOD1 levels were found for the SOD1 G37R liver, as well as, the SOD1 WT spinal cord and liver tissues (Fig. 4A, B) .
Although misfolded-SOD1 levels did not track with disease progression in the SOD1 G37R mice, to determine if any potential toxicity of soluble misfolded SOD1 in the SOD1 G37R mice could be attributable to bulk levels, we next compared total misfolded SOD1 levels in the spinal cords of these mice with the SOD1 WT mice using several different antibodies ( Fig. 4C-E) . Spinal cord samples were used from late-stage SOD1 G37R mice at 25 weeks of age and compared with SOD1 WT mice of the same age. With all three antibody types, soluble misfolded SOD1 levels appear elevated in the SOD1 WT spinal cord when compared to SOD1 G37R mice, where this was significant for the B8H10 and C4F6
antibodies (Fig. 4D, E) . Moreover, these increases in misfolded SOD1 levels were not related to expression levels of total human SOD1, which were not different between the SOD1 G37R and SOD1 WT mice (Fig. 4F) .
Therefore, these misfolded species being detected appear independent of total human SOD1 levels, and the ratio of misfolded SOD1 to human SOD1 is therefore significantly greater for the SOD1 WT spinal cord (Fig. 4G) . Considering that soluble misfolded SOD1 levels were lower in the SOD1 G37R spinal cord, even at disease end-stage, and the hemizygous SOD1 WT mice are phenotypically healthy, these data suggest that soluble misfolded SOD1 levels do not correspond to disease in the SOD1 G37R spinal cord.
Overexpression of hCTR1 in the SOD1
G37R spinal cord improves levels of bioavailable copper and SOD1 enzymatic function CTR1 is a key component of cellular copper homeostasis, and acts to import copper into the cell for trafficking to cuproenzymes that require it for their activity (Prohaska, 2008) . Previous work done by our group has demonstrated that overexpressing human CTR1 leads to a significant increase in spinal cord copper levels (Roberts et al., 2014) . Moreover, overexpressing hCTR1 in the SOD1 G37R mice significantly extended lifespan of the animals and improved their locomotive function (Roberts et al., 2014) . Further work performed with the coppercontaining compound Cu II (atsm), which is currently in clinical trials for the treatment of ALS, also extends the lifespan of mutant SOD1 mice, improves their locomotive function, and increases bioavailable copper levels in the CNS (Hilton et al., 2017; Mcallum et al., 2013; Roberts et al., 2014; Williams et al., 2016) In this study, we assessed SOD1 G37R mice overexpressing hCTR1 for its potential effect on cuproenzyme functionality. SOD1 G37R mice that also expressed hCTR1 (hCTR1xSOD1 G37R mice) showed significantly greater spinal cord copper levels compared to SOD1 G37R mice (Fig. 5A) , which was not observed in the non-disease affected liver tissue (Fig. 5E) . Specificity of hCTR1 for modulating copper was confirmed by showing that zinc, magnesium and selenium levels remained unchanged in the spinal cord (Fig. 5B-D ) and liver tissues (Fig. 5F-H ) compared to SOD1 G37R mice.
Overexpression of mutant SOD1 led to a decrease in expression of endogenous mouse SOD1 levels for the spinal cord tissue, irrespective of hCTR1 expression, but not the liver tissue (Fig. 5I, M) . Although levels of human SOD1 (Fig. 5J, N) and misfolded SOD1 using the B8H10 antibody (Fig. 5K, O) were unchanged for both tissues, overexpression of hCTR1 in the SOD1 G37R mice elicited a modest, but statistically significant, increase in SOD1 activity selectively for the spinal cord ( Fig. 5L, P) . Whilst the overexpression of hCTR1 did not translate into an increase in human SOD1 levels in the spinal cord of SOD1 G37R mice, the improved copper levels did correspond to a slight improvement in SOD1 activity. This suggests that hCTR1 overexpression in these mice, leading to increased spinal cord copper availability, acted to partially restore the copper-dependent functionality of SOD1.
Overexpression of hCTR1 in the SOD1 G37R spinal cord restores impaired ceruloplasmin enzymatic function
Given the age-dependent accumulation of enzymatically inactive ceruloplasmin observed in the SOD1 G37R mouse spinal cord (Fig. 2) , we next investigated the impact of hCTR1 overexpression on ceruloplasmin function. As observed in Fig. 2 , the SOD1 G37R mice showed a significant increase in spinal cord ceruloplasmin levels, where this was decreased back to non-transgenic levels with hCTR1 overexpression (Fig. 6A) . Whilst overexpression of hCTR1 in the SOD1 G37R mouse spinal cord did not lead to a significant restoration in ceruloplasmin activity (Fig. 6B) , when expressed relative to protein levels this corresponded to a significant improvement in specific activity levels (Fig. 6C ). These changes in ceruloplasmin levels were shown to occur selectively in the spinal cord, with no difference in the liver tissue observed across all genotypes (Fig. 6D) , indicating a disease-affected spinal cord tissue effect on ceruloplasmin.
Discussion
Since its discovery as a genetic cause of ALS (Rosen et al., 1993) , SOD1 has played an important role in helping better understand the pathogenesis of ALS and in progressing the development of novel therapeutic strategies, including antisense oligonucleotides and gene therapy to eradicate mutant SOD1 (Chen et al., 2017; Ralph et al., 2005) . The expression of mutant SOD1 is an unequivocal cause of ALS in people, and the relationship between increased levels of mutant SOD1 and a worsening of disease phenotype in transgenic animal models appears to support a direct toxic gain of function.
However, treating with the copper-containing compound Cu II (atsm) extends survival and improves the ALS-like phenotype of mutant SOD1 transgenic mice whilst concomitantly increasing levels of mutant SOD1 (Hilton et al., 2017; Roberts et al., 2014; Williams et al., 2016) . These studies with Cu II (atsm) show that the increase in mutant SOD1 is due to an increase in the amount of copper-replete SOD1 and, therefore, that stabilisation of SOD1 through copper metalation is an effective way to mitigate the deleterious consequences of mutant SOD1 expression. Moreover, the outcomes reported for Cu II (atsm) in mutant SOD1 mice indicate that whether or not SOD1 is appropriately satiated for its requisite supply of copper may be more important than solely considering the bulk amount of mutant SOD1 present. These examinations of mutant SOD1 mice, therefore, have revealed that copper bioavailability in the CNS may play a significant role in the development of ALS.
Further to this, a role for copper in ALS could explain why the CNS is selectively affected by the disease. Despite being ubiquitously expressed, the symptomatic consequences of mutations to SOD1 manifest primarily as the deterioration of large motor neurones in the CNS. We have previously established that with mutant SOD1 overexpression, an increased copper requirement is placed on tissues to ensure the proper metalation of SOD1. Although in the peripheral tissues this demand appeared to be met, the CNS demonstrated a conspicuous inability to satisfy the elevated copper requirements which translated into greater SOD1 enzymatic dysfunction relative to peripheral tissues (Hilton et al., 2016) . The underlying basis for this insufficiency remains to be elucidated, but the naturally slow turnover rate of copper in the CNS (Levenson and Janghorbani, 1994 ) is likely to be a contributing factor.
In this study, we show that enzymatically inactive mutant SOD1 accumulates with disease progression selectively within the diseaseaffected spinal cord tissue. Furthermore, we show the progressive enzymatic dysfunction observed extends beyond SOD1 to also include the copper-dependent ferroxidase ceruloplasmin. Unlike SOD1 which requires only one copper ion for its catalytic activity, ceruloplasmin requires six (Hellman and Gitlin, 2002; Hellman et al., 2002) . Thus, and notwithstanding potential cell type specific phenomena, it is conceivable that a relatively moderate impediment to copper availability could have a greater impact on ceruloplasmin than on other cuproenzymes. This possibility is consistent with data presented in Figs. 1 and 2 which indicate the copper-dependent activity of ceruloplasmin is impaired to a greater extent than SOD1 in the spinal cords of the WT and non-transgenic (Non-Tg) control mice using the A5C3 (C), B8H10 (D) and C4F6 (E) antibodies and native gel conditions, as well as total human SOD1 using a non-conformation specific antibody and standard denaturing gel conditions (F). Western blot data shown in F are normalised to the loading control protein GAPDH. Relative abundance of misfolded SOD1 in spinal cord tissue (G) was determined by normalising data for misfolded SOD1 (from D) to total SOD1 levels (from F). P values shown indicate statistical different between indicated data sets. All data are presented as mean ± S.E.M; n = 8-9 individual animals in A, n = 5 individual animals in B, and n = 6 individual animals in C-G.
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G37R mice, and also by the data which show CCO activity is unaffected (Fig. 3) . The absence of a CCO change in standard mutant SOD1-expressing mice has been previously observed (Son et al., 2008; Williams et al., 2016) . However, a decrease in CCO activity has been reported in SOD1 G93A mice which also overexpress the human copper chaperone to SOD1 (CCS) (Son et al., 2008; Williams et al., 2016) . CCSxSOD1 G93A mice display a dramatically accelerated progression of disease symptoms, dying at~10 days of age compared to~130 days for mice overexpressing the SOD1 G93A transgene alone (Hilton et al., 2017; Williams et al., 2016) . Whilst the overexpression of mutant SOD1 has been shown to disrupt CNS copper trafficking protein and copper homeostasis (Tokuda et al., 2009; Tokuda et al., 2013) , it appears that concurrent overexpression of human CCS further compromises these pathways leading to substantial dysfunction of CCO. Considering the absence of change in SOD1 and ceruloplasmin for the SOD1 WT spinal cord (Figs. 1, 2) , this copper malfunction, which is exacerbated by human CCS overexpression, appears to be driven by a gain-of-function inherent to the SOD1 mutation and not just an increase in the additional load that SOD1 overexpression will place on the supply of endogenous copper. In contrast to the deleterious effect of CCS overexpression in SOD1 G93A mice, the overexpression of hCTR1 in SOD1 G37R mice improves animal phenotype (Roberts et al., 2014) , increases spinal cord copper levels (Fig. 5) , and partially restores copper-dependent functionality to SOD1 and ceruloplasmin (Figs. 5, 6) . Although the reasons underlying these distinct outcomes remain to be elucidated, these data collectively highlight the sensitivity of the CNS to perturbations in copper metabolism. Treatment with Cu II (atsm) also significantly improves mutant SOD1 mouse phenotype, as well as partially restoring SOD1 copper metalation and activity in the CNS (Hilton et al., 2017; Roberts et al., 2014; Soon et al., 2011; Williams et al., 2016) . As a result, these effects of Cu II (atsm) indicate a therapeutic benefit connected to copper availability and lend support to utilisation of this Fig. 5 . The effects of hCTR1 overexpression on copper levels, SOD1 protein levels and SOD1 functionality in spinal cords from SOD1 G37R mice. The influence of hCTR1 expression on copper, zinc, magnesium and selenium in spinal cord and liver tissue from 25-week old mice was determined by inductively coupled plasma mass spectrometry (A-H). Total levels of endogenous mouse SOD1 (I) and overexpressed human SOD1 (J) in spinal cord tissue were determined by standard denaturing gel and western blot conditions using a non-conformation specific SOD1 antibody. Levels of misfolded SOD1 in spinal cord tissue were determined using native gel conditions and the B8H10 antibody for misfolded SOD1 (K). SOD1 activity in spinal cord tissue was determined using the pyrogallol-based activity assay and for each mouse strain is expressed relative to activity measured in the non-transgenic (Non-Tg) control mice (L). Levels of endogenous mouse SOD1 (M), overexpressed human SOD1 (N), misfolded SOD1 (O) and SOD1 activity (P) were measured in liver tissue as per I-L. Quantitation of total endogenous mouse SOD1 and overexpressed human SOD1 was performed by normalising to the loading control protein GAPDH and expressing relative to non-transgenic (Non-Tg) controls. P values shown indicate statistical difference between indicated data sets. All data are presented as mean ± S.E.M; n = 5-6. approach in the treatment of ALS. Whilst the necessity for copper in the context of SOD1 is well understood, how copper bioavailability and metabolism may be affected more broadly in ALS -particularly for sporadic cases of unknown aetiology -remains to be established. However, some insight might be gleaned from the discovery of missense mutations to ATP7A being responsible for the development of X-linked distal motor neuropathy, a form of motor neurone disease (Kennerson et al., 2010) . ATP7A is a copper transporter purposed for maintaining intracellular copper homeostasis and delivering required copper to cuproenzymes for their catalytic activity (Kaler, 2011) . As a result, these missense mutations were seen to impair the copper transport functions of ATP7A and induce a progressive decline in spinal cord copper concentration (Hodgkinson et al., 2015; Kennerson et al., 2010) . Considering the cuproenzyme demand for catalytic copper, any disruption in ATP7A transport capacity would have an adverse effect on cuproenzyme functionality. This is particularly evident in the case of Menkes disease, where profound loss-of-function mutations to ATP7A cause severe systemic copper deficiency, and broad cuproenzyme dysfunction that rapidly results in progressive infantile neurodegeneration (Kaler, 2011) .
With regards to ALS, approximately 90% of all cases are termed sporadic and are of an unknown aetiology (Renton et al., 2014) . In its initial stages, Cu II (atsm) was used as a positron emitting tomography (PET) tracer to identify tumour blood flow and infer potential hypoxia (Holland et al., 2009; Lewis et al., 2008) . More recently however, administering 62 Cu-labelled Cu II (atsm) to patients with sporadic ALS produces PET scan images showing the selective retention of Cu II (atsm) within regions of the CNS, such as the motor cortex, directly affected in ALS (Ikawa et al., 2015) . The biochemical mechanisms governing this region-specific retention of Cu II (atsm) in the CNS of sporadic ALS patients have been attributed to an over-reductive state leading to oxidative stress and, potentially, the reduction and release of copper from the Cu II (atsm) (Donnelly et al., 2012; Ikawa et al., 2015; Obata et al., 2001) . If this occurs, the cellular trapping of copper released from Cu II (atsm) will presumably be increased in cells which contain an elevated concentration of copper-binding proteins which are not satiated for their copper requirements.
Conclusions
Copper is an essential element in eukaryotic biology; without it, eukaryotic organisms would not exist. The fundamental necessity for copper is exemplified by the extensive list of enzymes that require it for catalysis and the role of these enzymes in myriad vital processes (Festa and Thiele, 2011; Uauy et al., 1998) . In this study we demonstrate that enzymatic dysfunction in mutant SOD1 mice extends beyond SOD1 to include the cuproenzyme ceruloplasmin, which plays a key role in copper transport and iron metabolism. Improving levels of bioavailable copper through the overexpression of hCTR1 in SOD1 G37R mice restores
proper enzymatic function to both SOD1 and ceruloplasmin in the disease-affected spinal cord tissue. Ultimately, this study in the context of work showing a limited ability of the CNS to satisfy altered copper requirements driven by mutant SOD1 (Hilton et al., 2016) , the selective retention of Cu II (atsm) in the sporadic ALS-affected motor cortex (Ikawa et al., 2015) , and the therapeutic efficacy of Cu II (atsm) in mutant SOD1 mice (Hilton et al., 2017; Mcallum et al., 2013; Roberts et al., 2014; Soon et al., 2011) provides support for perturbations to copper availability potentially playing a significant role in ALS, including sporadic forms of the disease.
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